Details of Disease

General Information of Disease (ID: DISXRS8Y)

• Disease Name: Chronic pain
• Synonyms: chronic pain disease; chronic disorder involving pain; disorder involving pain, chronic
• Disease Class: MG30: Chronic pain
• Definition: Chronic form of disorder involving pain.
• Disease Hierarchy:
  DIS4RWOW: Pain
  DISXRS8Y: Chronic pain
• ICD Code:
  ICD-11: ICD-11: MG30
  ICD-10: ICD-10: R52.1, R52.2
  ICD-9: ICD-9: 338.2, 780
  Expand ICD-11: 'MG30
  Expand ICD-10: 'R52.1; 'R52.2
  Expand ICD-9: 338.2,780
• Disease Identifiers:
  MONDO ID: MONDO_0024317
  UMLS CUI: C1298685
  MedGen ID: 720585
  HPO ID: HP:0012532
  SNOMED CT ID: 373621006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 15 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bupivacaine	DM4PRFC	Approved	Small molecular drug	[1]
Buprenorphine	DMPRI8G	Approved	Small molecular drug	[2]
Diflunisal	DM7EN8I	Approved	Small molecular drug	[3]
Ethanol	DMDRQZU	Approved	Small molecular drug	[4]
Fentanyl	DM8WAHT	Approved	Small molecular drug	[5]
Hydromorphone	DMHP21E	Approved	Small molecular drug	[5]
Ketamine	DMT5HA4	Approved	Small molecular drug	[6]
Lidocaine	DML4ZOT	Approved	Small molecular drug	[7]
Morphine	DMRMS0L	Approved	Small molecular drug	[8]
Naltrexone	DMUL45H	Approved	Small molecular drug	[9]
Oxymorphone	DM65AGJ	Approved	Small molecular drug	[10]
Phenylbutazone	DMAYL0T	Approved	Small molecular drug	[11]
Pregabalin	DMDVP3B	Approved	Small molecular drug	[12]
Tramadol	DMRQD04	Approved	Small molecular drug	[13]
Ziconotide	DMSLJP4	Approved	Small molecular drug	[14]

This Disease is Treated as An Indication in 22 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GSK2696273	DMP5O1U	Preregistration	NA	[15]
Egalet-002	DM912LR	Phase 3	NA	[5]
CR-845	DMJYTUQ	Phase 2/3	NA	[5]
A277	DMIYY96	Phase 2	Small molecule	[16]
BMS-690514	DMX302C	Phase 2	Small molecular drug	[17]
Omnitram	DMNT3XN	Phase 2	NA	[5]
PF-05089771	DMD74BJ	Phase 2	NA	[18]
PF-06372865	DMT9FNB	Phase 2	NA	[19]
REL-1015	DM70AWR	Phase 2	NA	[5]
V120083	DM3RB6M	Phase 2	NA	[5]
COL-195	DML7MPQ	Phase 1/2	NA	[5]
ABT-102	DMJFWPR	Phase 1	Small molecular drug	[20]
ABT-110	DM1F50I	Phase 1	NA	[21]
CA-011	DMPQ1TM	Phase 1	NA	[5]
CNTX-0290	DMJPEVA	Phase 1	NA	[5]
Debio 0827	DMQIEFB	Phase 1	NA	[22]
Egalet-004	DMFTQKV	Phase 1	NA	[5]
GDC0310	DMUNFEP	Phase 1	NA	[5]
PF-06305591	DMR7ICW	Phase 1	NA	[23]
PF614	DM8CSWD	Phase 1	NA	[5]
REL-1028	DMPU43M	Phase 1	NA	[5]
TRV734	DMHD8CF	Phase 1	NA	[5]

This Disease is Treated as An Indication in 69 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
3-amino-5-benzyl-substituted indazole derivative 1	DMFDURZ	Patented	NA	[24]
Azaindazole amide derivative 1	DMJWH4B	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 1	DMTBWC9	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 2	DM5MT4R	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 3	DM54EV2	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 4	DMUBDYG	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 5	DMFOVPT	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 6	DMQGYWV	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 7	DMM1LKF	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 8	DMVBQJ1	Patented	NA	[24]
Bicyclic heteroaryl benzamide derivative 9	DMGONY4	Patented	NA	[24]
Five membered heterocyclic benzamide derivative 1	DMPFAST	Patented	NA	[24]
Five membered heterocyclic benzamide derivative 2	DM4U63E	Patented	NA	[24]
Five membered heterocyclic benzamide derivative 3	DMUS4Z0	Patented	NA	[24]
Imidazo pyridine derivative 1	DMCXHGW	Patented	NA	[24]
N-(phenylpyrazolyl)benzamide derivative 1	DM0ZJX7	Patented	NA	[24]
N-acylpiperidine ether derivative 1	DM5GCUR	Patented	NA	[24]
N-acylpiperidine ether derivative 2	DM02RQ4	Patented	NA	[24]
N-acylpiperidine ether derivative 3	DMXWE5R	Patented	NA	[24]
N-acylpiperidine ether derivative 4	DMBUQDR	Patented	NA	[24]
N-acylpiperidine ether derivative 5	DMQ2MKT	Patented	NA	[24]
N-acylpiperidine ether derivative 6	DMAS01P	Patented	NA	[24]
N-acylpiperidine ether derivative 7	DMCJR4N	Patented	NA	[24]
N-acylpyrrolidine ether derivative 1	DMQ4ULC	Patented	NA	[24]
N-acylpyrrolidine ether derivative 2	DMK4Y71	Patented	NA	[24]
PMID28270021-Compound-WO2010077680 103	DM437ZC	Patented	NA	[24]
PMID28270021-Compound-WO2010077680 109	DMNUA21	Patented	NA	[24]
PMID28270021-Compound-WO2010077680 201	DMQAZMC	Patented	NA	[24]
PMID28270021-Compound-WO2010077680 481	DM6VAS2	Patented	NA	[24]
PMID28270021-Compound-WO2010077680 495	DMQ9CBS	Patented	NA	[24]
PMID28270021-Compound-WO2010077680 803	DM6TJU0	Patented	NA	[24]
PMID28270021-Compound-WO2010077680 811	DM47FNS	Patented	NA	[24]
PMID28270021-Compound-WO2013009582Example16	DMVS7CJ	Patented	NA	[24]
PMID28270021-Compound-WO2013009582Example76	DMQK4IX	Patented	NA	[24]
PMID28270021-Compound-WO2013161919Example85-117	DM2XKTB	Patented	NA	[24]
PMID28270021-Compound-WO2014078408Example1	DMO02EL	Patented	NA	[24]
PMID28270021-Compound-WO2014078408Example26	DMVCBSK	Patented	NA	[24]
PMID28270021-Compound-WO2014129431Example8-1	DMKO4ZH	Patented	NA	[24]
PMID28270021-Compound-WO2014152663 701	DMA04P6	Patented	NA	[24]
PMID28270021-Compound-WO2015042088Example11	DM16URY	Patented	NA	[24]
PMID28270021-Compound-WO2015042088Example12	DMOZHGU	Patented	NA	[24]
PMID28270021-Compound-WO2015042088Example4	DM6KXOQ	Patented	NA	[24]
PMID28270021-Compound-WO2016054807Example1	DMD5QEL	Patented	NA	[24]
PMID28270021-Compound-WO2016054807Example112	DMW2ZRM	Patented	NA	[24]
PMID28270021-Compound-WO2016054807Example71	DMREZ9I	Patented	NA	[24]
PMID28270021-Compound-WO2016054807Example80	DMPI86D	Patented	NA	[24]
PMID28270021-Compound-WO2016054807Example82	DM9ADSN	Patented	NA	[24]
Pyrazolo[1,5-a]pyridine derivative 1	DMH1W89	Patented	NA	[24]
Pyrazolo[1,5-a]pyridine derivative 2	DMLS827	Patented	NA	[24]
Pyrazolo[4,3-c]pyridine derivative 1	DMHRUIZ	Patented	NA	[24]
Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1	DMTM82B	Patented	NA	[24]
Pyrido[3,2-d]pyrimidine derivative 2	DMRHAU4	Patented	NA	[24]
Pyrido[3,2-d]pyrimidine derivative 3	DM6D1XR	Patented	NA	[24]
Pyrrolo[2,3-b]pyridine derivative 1	DMVKCQU	Patented	NA	[24]
Pyrrolo[2,3-b]pyridine derivative 2	DM7IPWB	Patented	NA	[24]
Pyrrolo[2,3-b]pyridine derivative 3	DMCYOL7	Patented	NA	[24]
Pyrrolo[2,3-d]pyrimidine derivative 3	DMTX1G4	Patented	NA	[24]
Pyrrolo[2,3-d]pyrimidine derivative 4	DME0WSR	Patented	NA	[24]
Pyrrolo[3,2-c]pyridine derivative 1	DMKF8HI	Patented	NA	[24]
Six-membered heterocyclic benzamide derivative 1	DMYFK85	Patented	NA	[24]
Six-membered heterocyclic benzamide derivative 2	DMX6AKV	Patented	NA	[24]
Six-membered heterocyclic benzamide derivative 3	DMEGVD4	Patented	NA	[24]
Six-membered heterocyclic benzamide derivative 4	DMB0D1H	Patented	NA	[24]
Six-membered heterocyclic benzamide derivative 5	DM0GTUH	Patented	NA	[24]
Six-membered heterocyclic benzamide derivative 6	DMZU96C	Patented	NA	[24]
Six-membered heterocyclic benzamide derivative 7	DM15AFI	Patented	NA	[24]
Tri-substituted urea derivative 1	DMHGRTX	Patented	NA	[24]
Tri-substituted urea derivative 2	DMUVPR8	Patented	NA	[24]
Triazolo[4,3-b]pyridazine derivative 2	DMMJ1FN	Patented	NA	[24]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AMG-517	DM3HB06	Discontinued in Phase 1	Small molecular drug	[25]

This Disease is Treated as An Indication in 3 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Oxycodone hydrochloride	DMCA7LN	Application submitted	NA	[5]
Remoxy ER	DMEEYR8	Application submitted	NA	[5]
SequestOx	DMCC5JU	Application submitted	NA	[5]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
SCN9A	TT4G2JS	Strong	Genetic Variation	[26]

References

• [1] Bupivacaine FDA Label
• [2] Buprenorphine FDA Label
• [3] Diflunisal FDA Label
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2299).
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Ketamine FDA Label
• [7] Lidocaine FDA Label
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [9] Naltrexone FDA Label
• [10] Oxymorphone FDA Label
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7270).
• [12] Pregabalin FDA Label
• [13] Tramadol FDA Label
• [14] Ziconotide FDA Label
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033647)
• [16] Clinical pipeline report, company report or official report of Klus Pharma
• [17] A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007 Jul 1;67(13):6253-62.
• [18] ClinicalTrials.gov (NCT01529346) Efficacy Of PF-05089771 In Treating Postoperative Dental Pain. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT02262754) PF-06372865 In Subjects With Chronic Low Back Pain. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT00854659) A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT00941746) Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain. U.S. National Institutes of Health.
• [22] Clinical pipeline report, company report or official report of Debiopharm (2011).
• [23] ClinicalTrials.gov (NCT01797796) Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare. U.S. National Institutes of Health.
• [24] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4129).
• [26] Polymorphism in the SCN9A voltage-gated sodium channel gene associated with interstitial cystitis/bladder pain syndrome.Urology. 2013 Jan;81(1):210.e1-4. doi: 10.1016/j.urology.2012.07.072. Epub 2012 Oct 24.